Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Cue Biopharma (Nasdaq: CUE) announced inducement equity awards on May 3, 2026, to seven new employees including newly appointed president and CEO Shao-Lee Lin, M.D., Ph.D. Grants include a non-statutory option for 655,074 shares and 327,537 RSUs for Dr. Lin, plus aggregate option grants of 518,599 shares and 327,534 RSUs to six other new employees. Options use an exercise price of $30.42 per share (May 1, 2026 close). Dr. Lin’s option vests monthly over four years; her RSUs were fully vested on grant. Other employees’ options vest quarterly over four years; their RSUs vested on grant.
AI-generated analysis. Not financial advice.
Positive
- Appointment of Shao-Lee Lin as president and CEO (leadership change)
- Dr. Lin received 327,537 restricted stock units fully vested upon grant
Negative
- Total non-statutory option grants equal 1,173,673 shares at $30.42 exercise price
- Total restricted stock units awarded equal 655,071 shares fully vested upon grant
News Market Reaction – CUE
On the day this news was published, CUE declined 2.04%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.4% during that session. Argus tracked a trough of -18.8% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $113.94M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Before this filing, CUE was up 5.15% while close peers were mixed: PDSB up 6.54%, ALXO down 10.53%, ACET and PYPD also down. Momentum scanner only flagged PYPD moving down, supporting a stock-specific move for CUE.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Private placement | Positive | +106.4% | Announced private placement expected to raise $30 million in gross proceeds. |
| Apr 30 | Pipeline expansion | Positive | +106.4% | Exclusive license for Ascendant-221 with milestones and global rights ex-Greater China. |
| Apr 30 | Leadership change | Positive | +106.4% | Appointment of Shao-Lee Lin as CEO and emphasis on clinical-stage transition. |
| Apr 22 | Reverse split | Negative | -6.0% | 1-for-30 reverse stock split to address Nasdaq minimum bid requirement. |
| Apr 15 | Preclinical data | Positive | +65.4% | New preclinical data on lead autoimmune candidate CUE-401 at IMMUNOLOGY2026. |
Recent corporate, financing, and pipeline updates have often coincided with large positive price reactions, while the reverse split drew a modest decline.
Over the past month, Cue Biopharma has reported multiple transformative events, including a 1-for-30 reverse split, a private placement targeting about $30 million, and an exclusive license for Phase 2 anti-IgE antibody Ascendant-221. The appointment of Shao-Lee Lin as CEO and preclinical CUE-401 data were accompanied by strong positive price moves. Today’s inducement grants tie directly to that leadership transition and the recently adopted 2026 Inducement Stock Incentive Plan referenced in an April 8-K.
Regulatory & Risk Context
Cue Biopharma has an effective S-3 shelf filed on 2026-03-17, registering up to $300,000,000 of securities, including an at-the-market facility for up to $12,666,282 of common stock with a 3.0% agent fee. No usage has been recorded yet, but this shelf enables future capital raises through debt, equity, or ATM sales.
Market Pulse Summary
This announcement details inducement equity awards for Cue Biopharma’s new CEO and six other hires under the 2026 Inducement Stock Incentive Plan, including options and fully vested RSUs. It follows recent transformative steps: a private placement targeting about $30 million, a Phase 2 asset license, a 1-for-30 reverse split, and an effective $300,000,000 S-3 shelf. Investors may watch how these hires support clinical execution and future financing decisions under the new leadership.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-statutory stock option financial
restricted stock units financial
nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company’s 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grants made to Dr. Lin consisted of (i) a non-statutory stock option to purchase 655,074 shares of common stock, at an exercise price of
The inducement grants made to the six other new employees consisted of (i) non-statutory stock options to purchase an aggregate of 518,599 shares of common stock, at an exercise price of
About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.
Investor and Media Contact
ir@cuebio.com
Cue Biopharma, Inc.
